Regimens for immunisation with meningococcal conjugates
AssigneeGlaxosmithkline Biologicals SA
InventorLisa Danzig
Life of this patent
Estimating the term…
Abstract
Multivalent meningococcal conjugate vaccines are administered according to a schedule in which a first dose is administered to a patient aged between 0 and 12 months, and a second dose is administered to the patient aged between 12 and 24 months.
Claims6
A method of immunizing a human patient, comprising:
- (a) administering a multivalent meningococcal capsular saccharide-carrier protein conjugate vaccine to the patient when said patient is about 6 months of age, and (b) administering the multivalent meningococcal capsular saccharide-carrier protein conjugate vaccine to the patient when said patient is about 12 months of age, wherein the multivalent meningococcal capsular saccharide-carrier protein conjugate vaccine includes capsular saccharide-carrier protein conjugates of meningococcal serogroups A, C, W135 and Y.
A method of immunizing a human patient who previously received a multivalent meningococcal capsular saccharide-carrier protein conjugate vaccine when said patient was about 6 months of age, comprising administering the multivalent meningococcal capsular saccharide-carrier protein conjugate vaccine to the patient when said patient is about 12 months of age, wherein the multivalent meningococcal capsular saccharide-carrier protein conjugate vaccine includes capsular saccharide-carrier protein conjugates of all four of meningococcal serogroups A, C, W135 and Y.
Dependencies are inferred from the claim text.